Skip to main content
SpringerLink
Log in

Genetically determined sparteine oxidation polymorphism in a Polish population

  • Letters To The Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

The genetic oxidation polymorphism was determined in 160 healthy Polish volunteers from the southwest of Poland (Wrocław region), using sparteine as a model drug. The results of a Polish population study revealed a bimodal distribution of the sparteine metabolic ratio and showed the existence of two oxidation phenotypes designated as extensive and poor metabolizers. The frequency of poor metabolizers in our study (8.8%) compares well with most results of poor oxidation metabolizers in Caucasian populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105

    Google Scholar 

  2. Eichelbaum M, Reetz KP, Schmidt EK, Zekorn C (1986) The genetic polymorphism of sparteine metabolism. Xenobiotica 16: 465–481

    Google Scholar 

  3. Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F (1988) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44: 431–435

    Google Scholar 

  4. Brosen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 57: 357–360

    Google Scholar 

  5. Benitez J, Llerena A, Cobaleda J (1988) Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther 44: 74–77

    Google Scholar 

  6. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187

    Google Scholar 

  7. Paar WD, Schuhler H, Fimmers R, Dengler HJ (1989) Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma. Eur J Clin Pharmacol 36: 555–560

    Google Scholar 

  8. Inaba T, Vinks A, Otton SV, Kalow W (1983) Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther 33: 394–399

    Google Scholar 

  9. Dick B, Küpfer A, Molnar J, Braunschweig S, Preisig R (1982) Hydroxylierungsdefekt für Medikamente (Typus Debrisoquin) in einer Stichprobe der Schweizer Bevölkerung. Schweiz Med Wochenschr 112, 1061–1067

    Google Scholar 

  10. Kallio J, Lindberg R, Huupponen R, Isalo E (1988) Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Br J Clin Pharmacol 26: 791–795

    Google Scholar 

  11. Nakamura K, Goto F, Ray WA, Mc Allister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408

    Google Scholar 

  12. Peart GF, Boutagy J, Shenfield GM (1986) Debrisoquine oxidation in an Australian population. Br J Clin Pharmacol 21: 465–471

    Google Scholar 

  13. Vinks A, Inaba T, Otton SV, Kalow W (1982) Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 31: 23–29

    Google Scholar 

  14. Holland P, Barry M, Teely J (1991) Pharmacogenetics and drug metabolism: an Irish perspective. Ir J Med Sci 160: 54–56

    Google Scholar 

  15. Spina E, Campo GM, Calandra S, Caputi AP, Carillo JA, Benitez J (1992) Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients. Pharmacol Res 25: 43–49

    Google Scholar 

  16. Vincent-Viry M, Muller J, Fournier B, Galteau MM, Siest G (1991) Relation between debrisoquine oxidation phenotype and morphological, biological and pathological variables in a large population. Clin Chem 37: 327–332

    Google Scholar 

  17. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II: 584–586

    Google Scholar 

  18. Wanwimolruk S, Denton JR, Ferry DG, Beasley M, Broughton JR (1992) Polymorphism of debrisoquine oxidation in New Zealand Caucasians. Eur J Clin Pharmacol 42: 349–350

    Google Scholar 

  19. Brosen K (1986) Sparteine oxidation polymorphism in Greenlanders living in Denmark. Br J Clin Pharmacol 22: 415–419

    Google Scholar 

  20. Clasen K, Madsen L, Brosen K, Alboge K, Misfeldt S, Gram L (1991) Sparteine and mephenytoin oxidation: genetic polymorphisms in East and West Greenland Clin Pharmacol Ther 49: 624–630

    Google Scholar 

  21. Lou YC, Ying L, Bertilsson L, Sjöqvist F (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet II: 852–853

    Google Scholar 

  22. Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ (1987) Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 23: 482–485

    Google Scholar 

  23. Horai Y, Ishizaki T, Eichelbaum M, Hashimoto K, Chiba K, Dengler HJ (1989) Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations. Xenobiotica 18: 1077–1084

    Google Scholar 

  24. Mahgoub A, Idle JR, Smith RL (1979) A population and family study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica 9: 811–818

    Google Scholar 

  25. Eichelbaum M, Woodhouse NM (1985) Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol 28: 79–83

    Google Scholar 

  26. Islam SJ, Idle JR, Smith RL (1980) The polymorphic 4-hydroxylation of debrisoquine in a Saudi Arab population. Xenobiotica 10: 819–825

    Google Scholar 

  27. Sommers DK, Moncrieff J, Avenant J (1990) Polymorphism in sparteine oxidation in the Barakwena (Kwengo) of Southern Africa. South Africa J Sci 86: 28–29

    Google Scholar 

  28. Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol Ther 46: 377–394

    Google Scholar 

  29. Eichelbaum M, Gross AS, Kroemer HK (1992) Genetic polymorphism in drug metabolism and its role in patient medication. In: Crommelin DIA, Midha KK (eds) Topics in pharmaceutical sciences 1991. Medpharm, Stuttgart

    Google Scholar 

  30. Horai Y, Ishizaki T (1988) Pharmacogenetics and its clinical implications. II. Oxidation polymorphism. Ration Drug Ther 22: 1–8

    Google Scholar 

  31. Alvan G (1991) Clinical consequences of polymorphic drug oxidation. Fundam Clin Pharmacol 5: 209–228

    Google Scholar 

  32. Brosen K (1993) Isozyme specific drug oxidation: genetic polymorphism and drug drug interactions. Nord J Psychiatry 47 [Suppl 30]: 21–26

    Google Scholar 

  33. Orzechowska-Juzwenko K (1992) Clinical consequences of the genetically determined drug oxidation polymorphism. Pol Tyg Lek 47: 1173–1178

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Medical Academy, Wrocław, Poland

    K. Orzechowska-Juzwenko, J. Pawlik, P. Niewiński, P. Milejski, J. Dembowski, J. Turek, A. Goździk, L. Swiebodzki & Z. Hora

Authors
  1. K. Orzechowska-Juzwenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Pawlik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Niewiński
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Milejski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Dembowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Turek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Goździk
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Swiebodzki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Z. Hora
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orzechowska-Juzwenko, K., Pawlik, J., Niewiński, P. et al. Genetically determined sparteine oxidation polymorphism in a Polish population. Eur J Clin Pharmacol 46, 481–483 (1994). https://doi.org/10.1007/BF00191917

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00191917

Key words

Search

Navigation